関連する実験動画

Updated: Jul 30, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

エタムボトールとイソニアジドをリファンピシンとイソニアジドと比較して,抗結核治療の継続治療において

A W Lees, G W Allan, J Smith

    Lancet (London, England)
    |June 11, 1977
    PubMed
    まとめ

    この研究では,エタムボトールとイソニアジド (E+I) が,リファンピシンとイソニアジド (R+I) の費用対効果の高い代替品であり,結核治療の完了のために,再発なしの有効性と受容性が同じであることを示しました.

    さらに関連する動画

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

    Published on: August 16, 2021

    Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells10:24

    Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

    Published on: May 22, 2026

    関連する概念動画

    Pulmonary Tuberculosis I01:29

    Pulmonary Tuberculosis I

    Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
    Causative Organism
    The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
    Mode of...
    Pulmonary Tuberculosis II01:28

    Pulmonary Tuberculosis II

    Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
    Here is a detailed explanation of its pathophysiology:
    Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
    Pulmonary Tuberculosis IV01:26

    Pulmonary Tuberculosis IV

    Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
    Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
    Pulmonary Tuberculosis V01:28

    Pulmonary Tuberculosis V

    Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
    Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
    Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

    Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

    Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
    Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

    Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

    Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.